{"id":513994,"date":"2021-07-15T22:37:03","date_gmt":"2021-07-16T02:37:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/"},"modified":"2021-07-15T22:37:03","modified_gmt":"2021-07-16T02:37:03","slug":"imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/","title":{"rendered":"Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock"},"content":{"rendered":"

<\/p>\n

Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock<\/b><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE<\/a>)–
\nImago BioSciences, Inc. (\u201cImago\u201d), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the pricing of its upsized initial public offering of 8,400,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Imago, are expected to be $134.4 million, excluding any exercise of the underwriters\u2019 option to purchase additional shares. All of the shares of common stock are being offered by Imago. Imago has also granted the underwriters a 30-day option to purchase from Imago up to an additional 1,260,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Imago\u2019s common stock has been approved for listing on the Nasdaq Global Select Market and is expected to begin trading under the symbol \u201cIMGO\u201d on July 16, 2021. The offering is expected to close on July 20, 2021, subject to satisfaction of customary closing conditions.\n<\/p>\n

\nJefferies, Cowen, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering.\n<\/p>\n

\nA registration statement relating to the securities has been filed with the Securities and Exchange Commission and became effective on July 15, 2021. The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from: Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at Prospectus_Department@Jefferies.com<\/a> or by phone at 877-821-7388; or Cowen and Company, LLC, c\/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com<\/a>; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com<\/a>; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com<\/a>.\n<\/p>\n

\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210715006139\/en\/<\/a><\/span><\/p>\n

\nMatthew Plunkett, PhD
\n
Chief Financial Officer, Imago Biosciences
\n
matthew.plunkett@imagobio.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Hospitals Health Pharmaceutical Medical Supplies<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Imago BioSciences, Inc. (\u201cImago\u201d), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the pricing of its upsized initial public offering of 8,400,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Imago, are expected to be $134.4 million, excluding any exercise of the underwriters\u2019 option to purchase additional shares. All of the shares of common stock are being offered by Imago. Imago has also granted the underwriters a 30-day option … <\/p>\n

Continue reading “Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-513994","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Imago BioSciences, Inc. (\u201cImago\u201d), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the pricing of its upsized initial public offering of 8,400,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Imago, are expected to be $134.4 million, excluding any exercise of the underwriters\u2019 option to purchase additional shares. All of the shares of common stock are being offered by Imago. Imago has also granted the underwriters a 30-day option … Continue reading "Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-16T02:37:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210715006139r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock\",\"datePublished\":\"2021-07-16T02:37:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\\\/\"},\"wordCount\":464,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210715006139r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\\\/\",\"name\":\"Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210715006139r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-07-16T02:37:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210715006139r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210715006139r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/","og_locale":"en_US","og_type":"article","og_title":"Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock - Market Newsdesk","og_description":"Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Imago BioSciences, Inc. (\u201cImago\u201d), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the pricing of its upsized initial public offering of 8,400,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Imago, are expected to be $134.4 million, excluding any exercise of the underwriters\u2019 option to purchase additional shares. All of the shares of common stock are being offered by Imago. Imago has also granted the underwriters a 30-day option … Continue reading \"Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-16T02:37:03+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210715006139r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock","datePublished":"2021-07-16T02:37:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/"},"wordCount":464,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210715006139r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/","name":"Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210715006139r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-07-16T02:37:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210715006139r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210715006139r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/513994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=513994"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/513994\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=513994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=513994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=513994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}